ClinicalTrials.gg
WithdrawnNCT04760288AcceleRET-MTCUpdated Jan 5, 2024

A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

A Phase 3 interventional study of Pralsetinib and Cabozantinib in Medullary Thyroid Cancer, sponsored by Hoffmann-La Roche. Withdrawn at 1 site in Spain. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-01-05.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Due to several logistical challenges during start-up which could not be overcome study was withdrawn.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Carcinoma, Medullary with a site in Spain — none open to participants now, 5 under way, 1 of them phase 3. Carcinoma, Medullary · Spain.

Enrollment
11th of 11
0 · median 247
Started
2023
the only one that year
Phase 3
4 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
2 of 15
Hoffmann-La Roche

Among the 15 studies in Carcinoma, Medullary with a site in Spain, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 4 in phase 3, and was the 13th registered.

Carcinoma, Medullary

144 studies on the registry are indexed under Carcinoma, Medullary; 30 are open to participants now.

Browse Carcinoma, Medullary studies →

Open to participants now

None of the 15 studies in Carcinoma, Medullary with a site in Spain is open now. The open studies under Carcinoma, Medullary, anywhere →

Who these studies take

Of the 16 Carcinoma, Medullary studies recruiting now, 9 (56%) set no upper age limit and 3 (19%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 15 studies in Carcinoma, Medullary with a site in Spain as a file.
02

Study summary

A study to evaluate the efficacy and safety of pralsetinib compared with SOC treatment (cabozantinib or vandetanib) for participants with RET (rearranged during transfection)-mutant MTC who have not previously received a SOC MultiKinase Inhibitor (MKI) therapy. Participants will be randomized in a 1:1 ratio into one of two treatment arms: Arm A (pralsetinib) or Arm B (investigator's choice of either cabozantinib or vandetanib for adults and vandetanib for adolescents). Participants whose disease progresses during SOC treatment will be offered the option to cross over to receive pralsetinib after confirmation of progressive disease by blinded independent central review (BICR).

03

Conditions studied

  • Medullary Thyroid Cancer

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must have confirmed unresectable locally advanced or MTC and be a candidate for systemic therapy with SOC MKI.
  • Must have received no prior systemic anticancer treatment with MKI therapies for advanced or metastatic MTC.
  • Must have radiologically confirmed progressive disease within the last 14 months and at least one of the following:

    1. A MTC-associated symptom and
    2. CLN (Calcitonin) and CEA (carcinoembryonic antigen) level doubling time of less than 24 months.
  • Confirmed RET mutation.
  • Must be able to swallow an oral medication.
  • Must have an (Eastern Cooperative Oncology Group) Performance Status of 0-2.
  • For women of : agreement to remain abstinent (refrain from heterosexual intercourse) or use appropriate during the treatment period and for the respective period of time after final dose of study drug.
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use appropriate contraception during the treatment period and for the respective period of time after final dose of study drug and to refrain from donating sperm.

Exclusion criteria

Exclusion Criteria:

  • Participants who are pregnant or breastfeeding, or intending to become pregnant during the study within 14 days after the final dose of pralsetinib or within 4 months after the final dose of vandetanib or cabozantinib.
  • Have disease that is suitable for surgery or radiotherapy administered with curative intent.
  • Have been previously treated with any systemic kinase inhibitor therapy regimens, including a selective RET inhibitor, given for recurrent and/or disease.
  • Have received any radiation therapy within 14 days prior to Day 1 of Cycle 1 and any related toxicity must be resolved to Grade 1 or better.
  • Participant's tumor has any additional known primary driver alterations other than RET.
  • Have known to pralsetinib, vandetanib, or cabozantinib, or any of their ingredients.
  • Have a history of pneumonitis of non-infectious etiology within the last 12 months.
  • Have ongoing treatment with chronic or systemic >10 mg/day.
  • Have any history of hereditary bleeding disorder or any evidence of hematemesis.
  • Have had major surgery or invasive dental procedure within 3 weeks prior to Day 1 of Cycle 1.
  • Have central nervous system (CNS) metastases that are associated with progressive neurologic symptoms, untreated spinal cord compression or requires increasing doses of corticosteroids to control the CNS disease.
  • Have , uncontrolled, cardiovascular disease.
  • Have required treatment with a prohibited medication or herbal remedy.
  • Have received hematopoietic growth factor support or transfusion within 14 days of the first dose of study drug.
  • Had a major surgical procedure within 14 days of the first dose of study drug.
  • Have a history of another primary that has been diagnosed or required therapy within the past 2 years before randomisation.
  • Have a serious infection requiring intravenous (IV) antibiotics within 7 days prior to initiation of study treatment.
  • Have an active, uncontrolled infection (viral, bacterial, or fungal) or is positive for /C infections (HBV/) or .
  • Have received organ or allogenic bone marrow or peripheral blood stem cell transplant.
  • Is a female who is unwilling to abstain from sexual intercourse or employ highly effective from the time of and for at least 4 months after the last dose of study drug.
  • Is a male who is unwilling to abstain from sexual intercourse or employ highly effective contraception from the time of informed consent and for at least 120 days after the final dose of study drug.
  • Have prior or ongoing clinically significant illness, medical condition, surgical history, physical finding, or laboratory abnormality that, in the Investigator's or Sponsor's opinion, could affect the safety of the patient or impair the assessment of study results.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Arm A (Pralsetinib)

    Participants will receive pralsetinib at a dose of 400 milligrams (mg) orally once daily (PO QD) in 28-day cycles.

    Drug: Pralsetinib

  • Active comparator
    Arm B (SOC: Cabozantinib/Vandetanib)

    Adult participants will receive investigator's choice of SOC MKI therapy with either 140 mg cabozantinib PO QD or 300 mg vandetanib PO QD in 28-day cycles. Adolescents participants (≥ 12 and \< 18 years of age) will receive vandetanib, PO QD or every other day, in 28-day cycles depending on the body surface area (BSA), at a dose determined according to the dosing nomogram available in the E.U. Vandetanib SmPC.

    Drug: Cabozantinib · Drug: Vandetanib

Interventions

  • Participants will receive pralsetinib at a dose of 400 mg, as per the dosing schedule described above.

  • Adult participants will receive cabozantinib at a dose of 140 mg, as per the dosing schedule described above.

  • Adult participants will receive vandetanib at a dose of 300 mg and adolescent participants will receive vandetanib as per the dosing schedule described above.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Defined as the time from randomization date to the first documented PD (Progression of Disease), as assessed by BICR according to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) or death due to any cause, whichever occurs first.

    Time frame: Up to 5 years

Secondary outcomes

  1. Time-To-Treatment Failure (TTF)

    Defined as the time from randomization date to the discontinuation of study drug during the treatment period due to death, treatment-related adverse event, or PD, as assessed by BICR according to RECIST v1.1, whichever occurs first.

    Time frame: Up to 13 years

  2. Objective Response Rate (ORR)

    Defined as the proportion of participants who achieve a CR (Complete Response) or a PR (Partial Response) prior to progressive disease and/or other anti-cancer therapy, as assessed by BICR according to RECIST v1.1.

    Time frame: Up to 13 years

  3. Overall Survival (OS)

    Defined as the time from randomization date to death due to any cause.

    Time frame: Up to 13 years

  4. Percentage of Participants With Adverse Events (AEs)

    Incidence and severity determined according to the NCI CTCAE v5.0 (National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0) criteria.

    Time frame: Up to 13 years

  5. Duration of Response (DOR)

    Defined as the number of weeks from the time criteria are first met for either a CR or a PR, until the date of documented PD, as assessed by BICR according to RECIST v1.1, or death due to any cause, whichever occurs first.

    Time frame: Up to 13 years

  6. Disease Control Rate (DCR)

    Defined as the proportion of participants who experience a best response of CR, PR, or stable disease, as assessed by BICR according to RECIST v1.1.

    Time frame: Up to 13 years

  7. Clinical Benefit Rate (CBR)

    Defined as the proportion of participants who experience a CR or a PR or a best response of stable disease with a minimum duration of 6 months, as assessed by BICR according to RECIST v1.1.

    Time frame: Up to 13 years

  8. Time to Deterioration of Function

    Defined as the time from randomization to the date of a participant's first \>= 10-point decrease from baseline score, as assessed through the use of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30).

    Time frame: Up to 13 years

  9. Quality of Life (QoL)

    Defined as the time from randomization to the date of a participant's first \>= 10-point decrease from baseline score, as assessed through the use of the GHS (Global Health Status)/QoL scales.

    Time frame: Up to 13 years

  10. Acceptability and Palatability of Pralsetinib Capsules

    Acceptability Survey scores on Day 1 of Cycle 1 and Crossover Cycle 1 (each cycle is 28 days).

    Time frame: Up to 13 years

07

Study locations

1 site
  • Hospital Universitario Virgen del Rocio
    Sevilla, 41013, Spain
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2023; primary completion for Oct 2027, 46 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2021
First posted
Feb 18, 2021
StartEst.
Nov 30, 2023
Primary completionEst.
Oct 6, 2027
CompletionEst.
Apr 12, 2035
Last update
Jan 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04760288
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 18, 2021
Start date
Nov 30, 2023 (estimated)
Primary completion
Oct 6, 2027 (estimated)
Completion
Apr 12, 2035 (estimated)
Last update
Jan 5, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralsetinib

Start the discussion